Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA

Cancer Gene Therapy

Volumn 13, Issue 3, 2006, Pages 234-241

  Yamato, K ^a   Fen, J ^b   Kobuchi, H ^b   Nasu, Y ^b   Yamada, T ^c   Nishihara, T ^d   Ikeda, Y ^c   Kizaki, M ^c   Yoshinouchi, M ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Cell growth; Cervical cancer; E6; Human papillomavirus 18; RNA interference; siRNA

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS;

ANIMALS; APOPTOSIS; CERCOPITHECUS AETHIOPS; COS CELLS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE SILENCING; HELA CELLS; HUMANS; ONCOGENE PROTEINS, VIRAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

CANCER VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 18;

EID: 32844470329     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700891     Document Type: Article

References (43)

1. de Villiers EM. Heterogeneity of the human papillomavirus group. J Virol 1989; 63: 4898-4903.
2. Fen J, Yoshinouchi M, Nakamura K, Kodama J, Nasu Y, Yamato K et al. Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. Oncol Rep 2004; 12: 375-379.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796-802.
4. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus. In: zur Hausen H (ed.), Human Pathogenic Papillomavirus. Springer-Verlag: Berlin, 1994, pp. 131-156.
5. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988; 48: 3780-3786.
6. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 1993; 7: 872-879.
7. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
8. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001; 114: 4557-4565.
9. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003; 63: 3919-3922.
10. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003; 63: 3593-3597.
11. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 2003; 22: 5694-5701.
12. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9: 1291-1300.
13. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002; 21: 6041-6048.
14. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003; 8: 762-768.
15. Pim D, Massimi P, Banks L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997; 15: 257-264.
16. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-7887.
17. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-5945.
18. Hall AH, Alexander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 2003; 77: 6066-6069.
19. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001; 114: 4557-4565.
20. Yamato K, Hashimoto S, Okahashi N, Ishisaki A, Nonaka K, Kizaki M et al. Dissociation of bone morphogenetic protein-mediated growth arrest and apoptosis of mouse B cells by HPV-16 E6/E7. Exp Cell Res 2000; 257: 198-205.
21. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993; 13: 775-784.
22. Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993; 13: 4918-4927.
23. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
24. Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003; 100: 7797-7802.
25. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327: 761-766.
26. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-644.
27. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8: 769-776.
28. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 2014-2018.
29. Takigawa Y, Nagano-Fujii M, Deng L, Hidajat R, Tanaka M, Mizuta H et al. Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol 2004; 48: 591-598.
30. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681-686.
31. Song E, Lee SK, Dykxhoorn DM, Novina C, Zhang D, Crawford K et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003; 77: 7174-7181.
32. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003; 13: 59-67.
33. Song S, Liem A, Miller JA, Lambert PF. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 2000; 267: 141-150.
34. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-4105.
35. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-937.
36. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915-1922.
37. Thomas M, Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 1999; 80(Part 6): 1513-1517.
38. Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA 1998; 95: 8058-8063.
39. Smotkin D, Prokoph H, Wettstein FO. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 1989; 63: 1441-1447.
40. Sherman L, Alloul N, Golan I, Durst M, Baram A. Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers. Int J Cancer 1992; 50: 356-364.
41. Schneider-Gadicke A, Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 1986; 5: 2285-2292.
42. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM, Arrand JR. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J Virol 1995; 69: 7023-7031.
43. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77: 1551-1563.